Clinical trials: CAKUT
Chronic Kidney Disease, Congenital Anomalies of Kidney and Urinary Tract
A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).
A phase 1, open-label safety, tolerability and early efficacy study of a Renal Autologous Cell Therapy (REACT) in patients with Chronic Kidney Disease from Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) (REGEN-004)
- Trial name
- NCT04115345
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Prokidney
Diabetic Kidney Disease, CAKUT
A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.
- Conditions
- Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases
- Trial name
- NCT05694169
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Prokidney